Results 81 to 90 of about 30,023 (217)
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
PLoS ONE, 2015 Delayed-release dimethyl fumarate (also known as gastro-resistant dimethyl fumarate), an oral therapeutic containing dimethyl fumarate (DMF) as the active ingredient, is currently approved for the treatment of relapsing multiple sclerosis.
Melanie S Brennan +7 more
doaj +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Breaking the cycle: reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate [PDF]
, 2019 Objective To infer molecular effectors of therapeutic effects and adverse events for dimethyl fumarate (DMF) in relapsing-remitting MS patients (RRMS) using untargeted plasma metabolomics.
David, M. J. +10 more
core +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Disease-modifying therapies alter gut microbial composition in MS. [PDF]
, 2019 Objective:To determine the effects of the disease-modifying therapies, glatiramer acetate (GA) and dimethyl fumarate (DMF), on the gut microbiota in patients with MS.
Baranzini, Sergio E +13 more
core
Fumarate Hydratase Loss Causes Combined Respiratory Chain Defects. [PDF]
, 2017 Fumarate hydratase (FH) is an enzyme of the tricarboxylic acid (TCA) cycle mutated in hereditary and sporadic cancers. Despite recent advances in understanding its role in tumorigenesis, the effects of FH loss on mitochondrial metabolism are still ...
Bridges, Hannah R +12 more
core +2 more sources
Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design [PDF]
, 2023 Robert Sharkus +3 more
openalex +1 more source
Recent Developments in the Field of Air‐Stable Nickel(0) Precatalysts for Cross‐Coupling Reactions
European Journal of Inorganic Chemistry, EarlyView.The development of bench‐stable Ni(0) sources aims to replace air‐sensitive [Ni(COD)2] (cod = cycloocta‐1,5‐diene) with easy‐to‐handle alternatives. Through a targeted ligand design, using electron‐deficient dienes, carbenes, and fluorophosphines, researchers have achieved air‐ and moisture‐tolerant complexes that show high catalytic activity in cross ...
Franziska Flecken, Schirin Hanf
wiley +1 more source
PLoS ONE, 2020 BackgroundSeveral disease modifying drugs (DMDs) have been approved for the treatment of multiple sclerosis (MS), however, little is known about their differential impact on peripheral blood (PB) B cell subsets.MethodsWe performed a cross sectional study
C L Kemmerer +8 more
doaj +1 more source